Actively Recruiting
Early Phase 1 Study of 99mTc-QULIC-5-P1 SPECT Imaging Compared With 68Ga-PSMA-11 PET in Men With PSMA Positive Prostate Cancer
Led by First Affiliated Hospital of Chongqing Medical University · Updated on 2025-06-04
30
Participants Needed
1
Research Sites
52 weeks
Total Duration
AI-Summary
What this Trial Is About
Researchers are evaluating a new imaging agent called 99mTc-QULIC-5-P1, a radiotracer that targets PSMA, which may help detect lesions in patients with PSMA positive prostate cancer. This early phase 1 study aims to investigate the safety, how the agent spreads in the body, and its usefulness in imaging prostate cancer compared with a standard PET scan agent called 68Ga-PSMA-11. Participants will receive a single intravenous injection of 99mTc-QULIC-5-P1. The study involves one study group where this radiotracer is administered once, followed by imaging procedures to assess its diagnostic capabilities. The comparison with 68Ga-PSMA-11 PET imaging will help understand the performance of the new tracer. During the study, participants will undergo diagnostic imaging to evaluate the presence and location of prostate cancer lesions. Researchers will monitor safety and efficacy outcomes over 15 days, focusing on diagnostic effectiveness. The study includes consent procedures and excludes those with certain medical conditions or lack of PSMA expression. Total participation duration varies but includes initial administration and follow-up for outcome assessment.
CONDITIONS
Brief Title
99mTc-QULIC-5-P1 SPECT Imaging in Patients With Prostate Cancer
Research Team
X
Xiaoyang Zhang, PhD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
